RedHill Biopharma Ltd. (NASDAQ:RDHL)‘s stock had its “buy” rating reissued by research analysts at FBR & Co in a research note issued on Wednesday.

Other equities research analysts also recently issued research reports about the company. Zacks Investment Research upgraded RedHill Biopharma from a “sell” rating to a “hold” rating in a report on Friday, August 26th. HC Wainwright set a $33.00 price objective on RedHill Biopharma and gave the company a “buy” rating in a report on Friday, October 7th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $26.25.

RedHill Biopharma (NASDAQ:RDHL) traded down 1.30% during midday trading on Wednesday, hitting $11.36. The company had a trading volume of 51,860 shares. The company’s market cap is $144.66 million. The firm has a 50-day moving average price of $13.09 and a 200-day moving average price of $12.82. RedHill Biopharma has a 12 month low of $8.10 and a 12 month high of $16.54.

Several hedge funds have recently made changes to their positions in the stock. Van ECK Associates Corp boosted its stake in shares of RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock worth $105,000 after buying an additional 138 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in shares of RedHill Biopharma during the second quarter worth about $142,000. Ingalls & Snyder LLC purchased a new stake in shares of RedHill Biopharma during the second quarter worth about $451,000. Finally, Bank Hapoalim BM boosted its stake in RedHill Biopharma by 221.7% in the third quarter. Bank Hapoalim BM now owns 147,504 shares of the company’s stock worth $2,049,000 after buying an additional 101,654 shares during the last quarter. 15.28% of the stock is owned by hedge funds and other institutional investors.

About RedHill Biopharma

RedHill Biopharma Ltd. is a biopharmaceutical company focused on the development and acquisition of late clinical-stage, orally administered drugs for the treatment of inflammatory and gastrointestinal diseases, and cancer. The Company’s products pipeline includes RHB-105, RHB-104, BEKINDA, RHB-106, YELIVA (ABC294640), MESUPRON, RP101, RIZAPORT and RHB-101.

5 Day Chart for NASDAQ:RDHL

Receive News & Stock Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related stocks with our FREE daily email newsletter.